TriangleHEALTH PROFESSIONAL · SOURCE READING
Gemtuzumab ozogamicin
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The antibody-targeted chemotherapy agent gemtuzumab ozogamicin has been evaluated in patients who had relapsed AML and expressed CD33.
Evidence (gemtuzumab ozogamicin):
A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]
Source links and citations
A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]
The overall response rate was 26%. Thirty-five patients (13%) achieved a CR and 36 patients (13%) achieved a CR without platelet recovery. It is unclear whether the inadequate platelet recovery was the result of megakaryocyte toxic effects of gemtuzumab or subclinical residual leukemia. [22]
Source links and citations
The long-term outcomes of patients who receive gemtuzumab and achieve CR without platelet recovery are unclear. Gemtuzumab induces profound bone marrow aplasia similar to leukemia induction chemotherapy and also has substantial hepatic toxic effects, including hepatic veno-occlusive disease.[22][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice